These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
156 related items for PubMed ID: 15337916
1. Rate of palivizumab administration in accordance with current recommendations among hospitalized children. Moynihan JA, Kim TY, Young T, Checchia PA. J Pediatr Health Care; 2004; 18(5):224-7. PubMed ID: 15337916 [Abstract] [Full Text] [Related]
2. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit? Geskey JM, Ceneviva GD, Brummel GL, Graff GR, Javier MC. Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776 [Abstract] [Full Text] [Related]
6. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S. Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710 [Abstract] [Full Text] [Related]
7. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile? Hashmi NA, Cosgrove JF, MacMahon P. Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917 [Abstract] [Full Text] [Related]
8. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis. Lacaze-Masmonteil T, Rozé JC, Fauroux B, French Pediatricians' Group of Sunagis Patients' Name-Based Programs. Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846 [Abstract] [Full Text] [Related]
13. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002. Henckel E, Luthander J, Berggren E, Kapadia H, Naver L, Norman M, Bennet R, Eriksson M. Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042 [Abstract] [Full Text] [Related]